BR112022027028A2 - Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de uso - Google Patents
Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de usoInfo
- Publication number
- BR112022027028A2 BR112022027028A2 BR112022027028A BR112022027028A BR112022027028A2 BR 112022027028 A2 BR112022027028 A2 BR 112022027028A2 BR 112022027028 A BR112022027028 A BR 112022027028A BR 112022027028 A BR112022027028 A BR 112022027028A BR 112022027028 A2 BR112022027028 A2 BR 112022027028A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- life
- methods
- felines
- increase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063050535P | 2020-07-10 | 2020-07-10 | |
| US202163143720P | 2021-01-29 | 2021-01-29 | |
| PCT/US2021/038714 WO2022010652A1 (en) | 2020-07-10 | 2021-06-23 | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022027028A2 true BR112022027028A2 (pt) | 2023-03-07 |
Family
ID=77043030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022027028A BR112022027028A2 (pt) | 2020-07-10 | 2021-06-23 | Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de uso |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11498953B2 (https=) |
| EP (1) | EP4178977A1 (https=) |
| JP (1) | JP2023534636A (https=) |
| KR (1) | KR20230038522A (https=) |
| CN (2) | CN116096741B (https=) |
| AU (1) | AU2021306179A1 (https=) |
| BR (1) | BR112022027028A2 (https=) |
| CA (1) | CA3188448A1 (https=) |
| MX (1) | MX2023000500A (https=) |
| TW (1) | TW202216749A (https=) |
| WO (1) | WO2022010652A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| US12297272B2 (en) | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| CN113544153B (zh) | 2019-01-03 | 2024-12-10 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| CN120590527A (zh) | 2020-05-11 | 2025-09-05 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物和使用方法 |
| JP7796415B2 (ja) * | 2020-06-10 | 2026-01-09 | 株式会社バイカ・セラピュティクス | エリスロポエチンポリペプチドを含む融合タンパク質 |
| KR20230038522A (ko) | 2020-07-10 | 2023-03-20 | 인베티엑스 인코포레이티드 | 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법 |
| EP4255933A4 (en) * | 2020-12-07 | 2025-07-23 | Invetx Inc | COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE |
| KR20230121056A (ko) * | 2020-12-18 | 2023-08-17 | 조에티스 서비시즈 엘엘씨 | 고양이 항체 불변 영역의 돌연변이 |
| WO2024145280A2 (en) | 2022-12-27 | 2024-07-04 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| AU2024210302A1 (en) | 2023-01-20 | 2025-09-04 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
| EP4662227A1 (en) * | 2023-02-08 | 2025-12-17 | Levicept Limited | Fusion protein |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| ES2142801T3 (es) | 1991-03-11 | 2000-05-01 | Univ Georgia Res Found | Clonacion y expresion de luciferasa de renilla. |
| EP0759170B1 (en) | 1993-09-10 | 2008-07-09 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| IL129767A0 (en) | 1996-12-12 | 2000-02-29 | Prolume Ltd | Apparatus and method for detecting and identifying infectious agents |
| JP2002507410A (ja) | 1998-03-27 | 2002-03-12 | プロルーム・リミテッド | ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用 |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| AU2005274905B2 (en) * | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| AU2005285347A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8546543B2 (en) * | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| CN101098890B (zh) * | 2004-11-12 | 2012-07-18 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2411050A4 (en) | 2009-03-25 | 2013-07-17 | Vet Therapeutics Inc | ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE |
| WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| GB2504887B (en) | 2011-05-06 | 2016-02-03 | Nvip Pty Ltd | Anti-Nerve growth factor antibodies and methods of preparing and using the same |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20130129727A1 (en) | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| EP3194429A4 (en) | 2014-09-18 | 2018-06-13 | Askgene Pharma, Inc. | Novel feline erythropoietin receptor agonists |
| EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
| EP3481413A4 (en) | 2016-07-08 | 2020-01-08 | Askgene Pharma, Inc. | FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US20200181258A1 (en) | 2016-10-17 | 2020-06-11 | Vetoquinol Sa | Modified antibody constant region |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| US12297272B2 (en) | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| BR112020017701A2 (pt) | 2018-03-12 | 2020-12-29 | Zoetis Services Llc | Anticorpos anti-ngf e métodos dos mesmos |
| CA3093539A1 (en) | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
| JP2022500037A (ja) | 2018-09-14 | 2022-01-04 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のための抗ｉｌ４受容体抗体 |
| US20210388053A1 (en) | 2018-10-18 | 2021-12-16 | Kindred Biosciences, Inc. | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use |
| JP7536294B2 (ja) | 2018-12-05 | 2024-08-20 | 株式会社バイカ・セラピュティクス | 抗体のＦｃ領域改変体 |
| CN120904316A (zh) | 2018-12-27 | 2025-11-07 | 伊兰科美国公司 | 兽用IgG Fc变体 |
| CN113544153B (zh) | 2019-01-03 | 2024-12-10 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| WO2021165417A1 (en) | 2020-02-19 | 2021-08-26 | Adivo Gmbh | Modified fc regions |
| CN115996949A (zh) | 2020-04-17 | 2023-04-21 | 硕腾服务有限责任公司 | 犬抗体变异体 |
| MX2022012793A (es) | 2020-04-17 | 2022-11-07 | Zoetis Services Llc | Variantes de anticuerpos felinos. |
| CN120590527A (zh) | 2020-05-11 | 2025-09-05 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物和使用方法 |
| US20220119513A1 (en) | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| KR20230038522A (ko) | 2020-07-10 | 2023-03-20 | 인베티엑스 인코포레이티드 | 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법 |
| MX2023004020A (es) | 2020-10-07 | 2023-07-07 | Zoetis Services Llc | Anticuerpos anti-ngf y métodos para su uso. |
| TWI904261B (zh) | 2020-10-19 | 2025-11-11 | 美商碩騰服務公司 | 犬及貓抑瘤素Ｍ受體β之抗體及其用途 |
| KR20230121056A (ko) | 2020-12-18 | 2023-08-17 | 조에티스 서비시즈 엘엘씨 | 고양이 항체 불변 영역의 돌연변이 |
| CA3238769A1 (en) | 2021-11-23 | 2023-06-01 | William Brondyk | Anti-ngf antibodies and uses thereof |
-
2021
- 2021-06-23 KR KR1020237004652A patent/KR20230038522A/ko active Pending
- 2021-06-23 JP JP2023501003A patent/JP2023534636A/ja active Pending
- 2021-06-23 CA CA3188448A patent/CA3188448A1/en active Pending
- 2021-06-23 BR BR112022027028A patent/BR112022027028A2/pt unknown
- 2021-06-23 CN CN202180056036.XA patent/CN116096741B/zh active Active
- 2021-06-23 AU AU2021306179A patent/AU2021306179A1/en active Pending
- 2021-06-23 US US17/355,839 patent/US11498953B2/en active Active
- 2021-06-23 WO PCT/US2021/038714 patent/WO2022010652A1/en not_active Ceased
- 2021-06-23 CN CN202411349658.3A patent/CN119899259A/zh active Pending
- 2021-06-23 EP EP21745871.0A patent/EP4178977A1/en active Pending
- 2021-06-23 MX MX2023000500A patent/MX2023000500A/es unknown
- 2021-07-02 TW TW110124393A patent/TW202216749A/zh unknown
-
2022
- 2022-04-29 US US17/733,479 patent/US11739135B2/en active Active
- 2022-10-12 US US18/046,082 patent/US12344650B2/en active Active
-
2025
- 2025-06-09 US US19/232,626 patent/US20250304650A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230090405A1 (en) | 2023-03-23 |
| CA3188448A1 (en) | 2022-01-13 |
| US12344650B2 (en) | 2025-07-01 |
| WO2022010652A1 (en) | 2022-01-13 |
| US11739135B2 (en) | 2023-08-29 |
| MX2023000500A (es) | 2023-04-12 |
| US20220009994A1 (en) | 2022-01-13 |
| CN119899259A (zh) | 2025-04-29 |
| EP4178977A1 (en) | 2023-05-17 |
| US20250304650A1 (en) | 2025-10-02 |
| US20220259282A1 (en) | 2022-08-18 |
| US11498953B2 (en) | 2022-11-15 |
| CN116096741A (zh) | 2023-05-09 |
| AU2021306179A1 (en) | 2023-03-02 |
| KR20230038522A (ko) | 2023-03-20 |
| TW202216749A (zh) | 2022-05-01 |
| CN116096741B (zh) | 2024-10-18 |
| JP2023534636A (ja) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022027028A2 (pt) | Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de uso | |
| BR112022022922A2 (pt) | Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso | |
| MX2021008144A (es) | Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. | |
| BR112023022836A2 (pt) | Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso | |
| BR112022001359A2 (pt) | Método e composição para anticorpos anti-cd73 e variantes | |
| BR112022005173A2 (pt) | Imunocitocina compreendendo complexo de proteína heterodimérica baseado em il-15/il-15ra, ácidos nucleicos, vetor, método célula hospedeira, composições e usos associados | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| AU2018274216A1 (en) | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer | |
| BR112021016272A2 (pt) | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos | |
| BR112021019520A2 (pt) | Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica | |
| BR112021019471A2 (pt) | Composições imunoterapêuticas e uso das mesmas | |
| BR112013003823A2 (pt) | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados | |
| BR112012029689A2 (pt) | proteína de fusão sequência de polinucleotídeo, célula hospedeira, composição farmacêutica e uso. | |
| BR112018067977A2 (pt) | composições e métodos para imunoterapia para cd20 | |
| BRPI0518793A2 (pt) | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica | |
| MX386014B (es) | Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma. | |
| BRPI0912411B8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune | |
| BRPI0909123B8 (pt) | anticorpos monoclonais, vetor de expressão, célula hospedeira, composição farmacêutica, uso do referido anticorpo, kit de diagnóstico e métodos de ensaio para detectar a presença de epítopos de vírus de influenza a | |
| BR112019008351A2 (pt) | imunoglobulinas e usos das mesmas | |
| BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
| MX2018005063A (es) | Polipéptidos condicionalmente activos. | |
| DK519387D0 (da) | Farmaceutiske praeparater indeholdende propylenglycol og/eller polyethylenglycol og urinstof som aktive hovedbestanddele samt anvendelse deraf | |
| BR112022012205A2 (pt) | Compostos ativos para receptores nucleares | |
| BR112021012667A2 (pt) | Proteínas de ligação anti-pd-1 e métodos de uso destas |